Aleniglipron
GSBR-1290
Gasherbrum Bio, Inc · Phase 2 · Completed · Enrollment 58
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Arm 1: Participants will receive aleniglipron administered orally | Obesity + T2D | n/r | n/r | n/r | n/r |
| Arm 2: Participants will receive a placebo administered orally | Obesity + T2D | n/r | n/r | n/r | n/r |